Skip to main content

Praxis der Lipid senkenden Therapie in der kardiologischen Rehabilitation

  • Chapter
Der schwerkranke und multimorbide Herzpatient
  • 47 Accesses

Zusammenfassung

Die Lipidtherapie ist Bestandteil einer multifaktoriellen Intervention am globalen Risiko eines Patienten mit Arteriosklerose. Grundlage ist die Erkenntnis, dass die koronare Herzkrankheit sowie andere Manifestationen der Erkrankung von ihrem Wesen her zur Progredienz neigen. Wir verfügen heute über gesicherte Erkenntnisse, wie diese Progredienz aufzuhalten oder zu verlangsamen ist. Die zu erreichende Risikoverringerung dürfte klinisch umso relevanter ausfallen, je konsequenter alle gesicherten Maßnahmen der Sekundärprävention umgesetzt werden. Daraus ergeben sich Behandlungsziele, die heute im Sinn von Empfehlungen und Leitlinien in ausformulierter Form vorliegen. Zur Behandlung von Dyslipoproteinämien, über die im Folgenden referiert werden soll, verfügen wir heute über eine wissenschaftlich gut abgesicherte Datenlage, deren Umsetzen den Kriterien einer „evidence based medicine“ unterliegt und damit in der kardiologischen Rehabilitation obligatorisch ist.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bloomfield HR, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341: 410 - 418

    Article  Google Scholar 

  2. Buchwald H, Bourdages HR, Campos CT, Nguyen P, Williams SE, Boen JR (1996) Impact of cholesterol reduction on peripheral arterial disease in the program on the surgical control of the hyperlipidemias ( POSCH ). Surgery 120: 672-679

    Google Scholar 

  3. Clarke R, Frost C, Collins R, Appleby P, Peto R (1997) Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. BMJ 314: 112 - 117

    Article  PubMed  CAS  Google Scholar 

  4. Consensus Panel Statement (1996) Preventing heart attack and death in patients with coronary disease. Circulation 93: 2205 - 2211

    Google Scholar 

  5. Diabetes Atherosclerosis Intervention Study Group (2001) Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357: 907 - 910

    Google Scholar 

  6. Euroaspire I and II Group (2001) Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 357: 995 - 2001

    Google Scholar 

  7. Fruchart JC (2000) Are nuclear factors the ultimate targets of drugs affecting lipid metabolism? Curr Atherosclerosis Rep 2: 353 - 354

    Article  CAS  Google Scholar 

  8. Gohlke H, Kübler W, Mathes P, Meinertz T, Schuler G, Sauer G (2001) Empfehlungen zur umfassenden Risikoverringerung für Patienten mit koronarer Herzerkrankung, Gefäßerkrankungen and Diabetes. Herausgegeben vom Vorstand der Deutschen Gesellschaft für Kardiologie - Herz-and Kreislaufforschung. Z Kardiol 90: 148-149

    Google Scholar 

  9. Hahmann HW, Schätzer-Klotz D, Bunte T, Becker D, Schieffer HJ (1999) The significance of high levels of lipoprotein (a) compared with established risk factors in premature coronary artery disease - differences between men and women. Atherosclerosis 144: 221 - 228

    Article  PubMed  CAS  Google Scholar 

  10. Pedersen TR, Kjekshus J, Pyörälä K (1998) Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 81: 333 - 335

    Article  PubMed  CAS  Google Scholar 

  11. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100: 230 - 235

    PubMed  CAS  Google Scholar 

  12. Rosenson RS, Tangney CC (1998) Antiatherothrombotic properties of statins. JAMA 279: 1643 - 1650

    Article  PubMed  CAS  Google Scholar 

  13. Sacks FM, Pfeffer MA, Moye LA for the Cholesterol and Recurrent Events Trial Investigators (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001 - 1009

    CAS  Google Scholar 

  14. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383 - 1389

    Google Scholar 

  15. Shepherd J, Cobbe SM, Fort I, Isles CG, Lorimer AR, Macfartane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1303-1307

    Google Scholar 

  16. Task Force, Wood D, Baker G de, Faergeman O, Graham I, Mancia G, Pyorala K (1998) Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 19: 1434-1503

    Google Scholar 

  17. The LIPID Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N Engl J Med 339: 1349 - 1357

    Google Scholar 

  18. Treasure CB, Klein JL, William S, Weintraub MD, Talley JD, Stillabower ME, Kossinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW (1995) Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronoary artery disease. N Engl J Med 332: 481 - 487

    Article  PubMed  CAS  Google Scholar 

  19. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämälainen H, Ilanne-Parikka P, KeinänenKiukaanniemi S, Laakso M, Louheranta A, Rastas M, Saliminen V, Uusitupa M for the Finnish Diabetes Prevention Group (2001) Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343 - 1350

    Google Scholar 

  20. Vaughan CJ, Murphy MB, Buckley BM (1996) Statins do more than just lower cholesterol. Lancet 348: 1079 - 1082

    Article  PubMed  CAS  Google Scholar 

  21. Willich SN, Müller-Nordhorn J, Kulig M, Binting S, Gohlke H, Hahmann H, Bestehorn K, Krobot K, Völler H for the PIN Study Group (2001) Cardiac risk factors medication, and recurrent clinical events - a prospective cohort study. Euro Heart J 22: 307 - 314

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Steinkopff Verlag Darmstadt

About this chapter

Cite this chapter

Hahmann, H.W. (2001). Praxis der Lipid senkenden Therapie in der kardiologischen Rehabilitation. In: Rauch, B., Held, K. (eds) Der schwerkranke und multimorbide Herzpatient. Steinkopff. https://doi.org/10.1007/978-3-642-93723-1_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93723-1_20

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-7985-1323-5

  • Online ISBN: 978-3-642-93723-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics